KIT and neoplasm: Presumably, imatinib resistance is caused by either inadequate drug concentrations, associated secondary KIT mutations or activation of signaling pathways that by pass KIT, and higher drug concentrations are thought to inhibit tumor growth in relative rather than absolute imatinib resistance [84].